Please login to the form below

Not currently logged in
Email:
Password:

ALK Abello

This page shows the latest ALK Abello news and features for those working in and with pharma, biotech and healthcare.

Merck gets US green light for allergy immunotherapy

Merck gets US green light for allergy immunotherapy

Merck gets US green light for allergy immunotherapy. Expected to provide a significant boost to company's partner Alk-Abello. ... Merck &Co and Alk-Abello have been given the go-ahead by the US FDA to start selling their grass pollen allergy

Latest news

  • FDA backs a brace of allergy immunotherapies FDA backs a brace of allergy immunotherapies

    Turning to Grastek, which was originally developed by Danish drugmaker Alk-Abello, the panel recommended approval in people aged five to 65, once again on the proviso that those taking it

  • UK's MHRA reveals advertising lapses UK's MHRA reveals advertising lapses

    Lloyds. iMed Systems promotes allergy treatment. The first complaint upheld by the UK regulator covers a complaint made by Meda Pharmaceuticals and ALK Abello about iMed's promotion of its injectable

  • FDA to review Merck & Co's allergy immunotherapy FDA to review Merck & Co's allergy immunotherapy

    Both the ragweed and grass pollen immunotherapies are developed in partnership with Denmark-based firm ALK-Abello and Merck has rights to develop, market and distribute approved products in the US,

  • Three new members at ABPI Three new members at ABPI

    Three new members at ABPI. ALK- Abello, Shionogi and Randox join UK trade body. ... ALK- Abello is a specialist biopharma company, which is focused on the development of treatments for people with allergies.

  • FDA asks for more data on Merck & Co's Zetia combo

    The company licenses US, Canadian and Mexican rights to the AITs from Denmark-based ALK Abello.

More from news
Approximately 3 fully matching, plus 15 partially matching documents found.

Latest Intelligence

  • Deal Watch July 2016 Deal Watch July 2016

    And Finally, Reality Bites. ALK-Abello has issued a press release announcing that Merck &Co has walked away from the deal agreed in 2007 (with Schering-Plough) for the allergy treatments ... No sales figures have been released by either side, but

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • ALK-Abello appoints Søren Jelert as CFO ALK-Abello appoints Søren Jelert as CFO

    ALK-Abello appoints Søren Jelert as CFO. He will be based at the company’s headquarters in Denmark. ... Dansih allergy immunotherapy company ALK-Abello has appointed Søren Jelert as its new chief financial officer, a role that sees him succeed

  • Cello Health Consulting expands its UK team Cello Health Consulting expands its UK team

    Tarplee has over 30 years of life science industry experience and previously worked for the likes of Adherium, ALK Abello, Sanofi and Abbott.

  • ALK Abelló's John Tarplee joins Adherium ALK Abelló's John Tarplee joins Adherium

    ALK Abelló's John Tarplee joins Adherium. Becomes business development SVP for Europe. ... UK. He brings over 30 years of sales and market expansion expertise, most recently in the role of senior vice president at Danish immunotherapy company ALK

  • Lars Dreiøe joins Sobi in senior quality and compliance role Lars Dreiøe joins Sobi in senior quality and compliance role

    Lars Dreiøe joins Sobi in senior quality and compliance role. Moves to the Swedish rare diseases company from Denmark's ALK. ... He will join the firm in January from Danish allergy vaccine company ALK Abelló, where he was international head of quality.

  • ALK Abello appoints UK managing director ALK Abello appoints UK managing director

    ALK Abello appoints UK managing director. Sean Connor joins from Shire. ... ALK Abello has appointed Sean Connor to the role of UK managing director and director of international markets.

More from appointments
Approximately 2 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics